Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer.
Despite widespread interest, few serum biomarkers have been introduced to the clinic over the past 20 years. Each approach to ovarian cancer biomarker discovery has its own advantages and disadvantages and it seems likely that a global biomarker discovery platform that mines all possible sources for biomarkers might be more useful. Such data could be combined with information from relevant microarray data, bioinformatic analyses and literature searches. This proposed integrated systems biology approach has the potential to yield promising ovarian cancer markers for diagnosis, prognosis and monitoring of patients during therapy.